The Lundbeck, Chiesi Group and Li-Cor Biosciences-backed eye and bladder cancer therapeutics developer has filed to go public on Nasdaq in an offering with a $100m placeholder target.
Aura Biosciences, a US-based cancer therapy developer backed by pharmaceutical firms Lundbeck and Chiesi Group and scientific measurement system provider Li-Cor Biosciences, has filed for an initial public offering. The IPO has a $100m placeholder figure and is set to take place on the Nasdaq Global Market. Cowen, SVB Leerink and Evercore are serving as…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.